Dr. Hubert J. Ford III, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 176
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Miami, Lm Miller School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NC license 2004-01391 -
Critical Care Medicine (Internal Medicine) Physician
NC license 2004-01391 -
Internal Medicine Physician
NC license 2004-01391
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
- Rex Hospital Raleigh, NC
- Johnston Health Smithfield, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 176
- Services billed
- 559
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 141 | 88 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 32 | 15 |
| Established patient office or other outpatient visit, 40-54 minutes | 25 | 22 |
| Test to examine how well the lungs exchange gases | 14 | 14 |
| New patient office or other outpatient visit, 60-74 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tadalafil | 172 |
| Opsumit (macitentan) | 159 |
| Sildenafil Citrate Other prescribers in Chapel Hill, NC | 126 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Chapel Hill, NC | 109 |
| Furosemide Other prescribers in Chapel Hill, NC | 102 |
| Ambrisentan | 100 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Chapel Hill, NC | 86 |
| Adcirca (tadalafil) | 82 |
| Orenitram Er (treprostinil diolamine) | 81 |
| Adempas (riociguat) | 63 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 37 payments worth $24,192 in total to this clinician.
| Merck Sharp & Dohme LLC | $13,689 |
|---|---|
| United Therapeutics Corporation | $9,381 |
| Chiesi USA, Inc. | $446 |
| Pfizer Inc. | $406 |
| Bayer HealthCare Pharmaceuticals Inc. | $200 |
| Mannkind Corporation | $69.01 |
| Consulting Fee | $18,640 |
|---|---|
| Travel and Lodging | $4,722 |
| Food and Beverage | $830 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| United Therapeutics Corporation Aug 8, 2025 | Consulting Fee REMODULIN · Pulmonary Arterial Hypertension | $8,200 |
| Merck Sharp & Dohme LLC Apr 14, 2025 | Consulting Fee | $5,760 |
| Merck Sharp & Dohme LLC Oct 27, 2025 | Consulting Fee | $4,480 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $570 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind | $413 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind | $410 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $371 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $357 |
| United Therapeutics Corporation Aug 7, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Dallas, TX · in-kind | $345 |
| Chiesi USA, Inc. Dec 3, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $337 |
All 21 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Chiesi USA, Inc. Dec 3, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $337 |
| Merck Sharp & Dohme LLC Nov 12, 2025 | Travel and Lodging travel to Chicago, IL | $45.06 |
| Merck Sharp & Dohme LLC Oct 27, 2025 | Consulting Fee | $4,480 |
| Merck Sharp & Dohme LLC Oct 27, 2025 | Travel and Lodging travel to Chicago, IL | $150 |
| Merck Sharp & Dohme LLC Oct 17, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind | $176 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind | $413 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind | $410 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind | $267 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 30, 2025 | Consulting Fee Adempas · Cardio-pulmonary | $200 |
| United Therapeutics Corporation Aug 8, 2025 | Consulting Fee REMODULIN · Pulmonary Arterial Hypertension | $8,200 |
| United Therapeutics Corporation Aug 8, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Dallas, TX | $230 |
| United Therapeutics Corporation Aug 7, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Dallas, TX · in-kind | $345 |
| United Therapeutics Corporation Aug 7, 2025 | Travel and Lodging REMODULIN · Pulmonary Arterial Hypertension · travel to Dallas, TX · in-kind | $322 |
| Pfizer Inc. Jun 14, 2025 | Travel and Lodging travel to Prague, Czech Republic · in-kind | $203 |
| Pfizer Inc. Jun 14, 2025 | Travel and Lodging travel to Prague, Czech Republic · in-kind | $203 |
| Merck Sharp & Dohme LLC Apr 14, 2025 | Consulting Fee | $5,760 |
| Merck Sharp & Dohme LLC Apr 14, 2025 | Travel and Lodging travel to Boston, MA | $150 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $570 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $371 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $357 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $173 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $639,726 in research payments for these studies, mostly to the institutions running them.
- An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH
Merck Sharp & Dohme LLC - A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
United Therapeutics Corporation · Active, not recruiting · NCT05203510 - A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
Merck Sharp & Dohme LLC - A phase 1 randomized doubleblind placebocontrolled study to evaluate the safety tolerability pharmacokinetics and pharmacodynamics of single escalating doses of PF07868489 in healthy adult participants and repeat do…
Pfizer Inc. - Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies wi…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.